Showing 6931-6940 of 8468 results for "".
- Combined Ultrasound and Radiofrequency Promotes Greater Wrinkle Reductionhttps://practicaldermatology.com/news/combined-ultrasound-and-radiofrequency-promotes-greater-wrinkle-reduction/2462721/Using high-intensity focused ultrasound in conjunction with monopolar radiofrequency yielded greater skin tightening and wrinkle reduction than either modality alone, according to new data. High-intensity focused ultrasound (HIFU) and monopolar radiofrequency (RF) are both popular as non-
- Study: Cryomodulation May Curb Acne Inflammationhttps://practicaldermatology.com/news/study-cryomodulation-may-curb-acne-inflammation/2462718/Cryomodulation was associated with significant inflammation reduction in patients with acne vulgaris, based on data from a new pilot study presented at the American Society for Laser Medicine and Surgery 43rd Annual Conference on Energy-based Medicine and Science in Baltimore.
- Mechanical Micro-Coring Shows Promise for Neck Treatmenthttps://practicaldermatology.com/news/aslms-2024-mechanical-micro-coring-shows-promise-neck-treatment/2462716/Mechanical dermal micro-coring is a safe and effective option for improving skin laxity, texture, and wrinkles on the neck, based on new data appearing at the American Society for Laser Medicine and Surgery (ASLMS) 43rd Annual Conference on Energy-based Medicine and Science in Baltimor
- New Data Show Efficacy of Topical 0.1% Stabilized Bioactive Retinol for Photoaginghttps://practicaldermatology.com/news/analysis-data-shows-efficacy-topical-01-stabilized-bioactive-retinol-photoaging/2462643/A recent integrated analysis published in the Journal of Drugs in Dermatology showed the efficacy and tolerability of topical 0.1% stabilized bioactive retinol in countering the signs of photoaging. "Advances in formulation science have allowed the production of stabilized bioact
- ARCA biopharma and Oruka Therapeutics Announce Merger Agreementhttps://practicaldermatology.com/news/arca-biopharma-and-oruka-therapeutics-announce-merger-agreement/2462611/ARCA biopharma and Oruka Therapeutics, a privately held biotechnology company developing novel biologics designed to set a new standard for the treatm
- Deucravacitinib Improves Patient-Reported Outcomes for Psoriatic Arthritishttps://practicaldermatology.com/news/deucravacitinib-improves-patient-reported-outcomes-psoriatic-arthritis/2462540/Deucravacitinib, a TYK-2 inhibitor, was linked with significant improvements in patient-reported outcomes (PROs) in patients with active psoriatic arthritis (PsA), according to results from a phase 2 trial. To assess the effects of deucravacitinib in this patient population, the study aut
- Study: Pembrolizumab Shows Efficacy in Japanese Patients with Advanced Melanomahttps://practicaldermatology.com/news/study-pembrolizumab-shows-efficacy-japanese-patients-advanced-melanoma/2462539/A recent analysis of the phase 1b KEYNOTE-041 trial indicated effectiveness and tolerability of pembrolizumab in Japanese patients with advanced melanoma. Researchers conducted the study over a 12-month period. The study evaluated pembrolizumab's long-term efficacy and safety in individua
- Integrated Dermatology Appoints Tushar Ramani, MD, as CEOhttps://practicaldermatology.com/news/integrated-dermatology-appoints-tushar-ramani-md-ceo/2462493/Integrated Dermatology has announced the appointment of Tushar Ramani, MD, as the company's new chief executive officer (CEO). Dr. Ramani will be replacing Jeff Queen, who after two decades as CEO and executive chairman, is transitioning to the role of co-executive chairman of the Board alongside
- American Acne and Rosacea Society (AARS) Releases Response to FDA Citizen's Petition from Valisurehttps://practicaldermatology.com/news/aars-releases-response-to-citizens-petition/2462445/The American Acne and Rosacea Society (AARS) has issued a public response to a recent report from Valisure showing common acne prod
- Galderma Prices IPO; Will Start Trading on the Swiss Stock Exchange Todayhttps://practicaldermatology.com/news/galderma-prices-ipo-will-start-trading-on-the-swiss-stock-exchange-today/2462444/Dermatology leader Galderma Group announced the pricing of its initial public offering at CHF 53 ($59) per share in Switzerland. The shares will be listed and start trading under the ticker symbol “GALD” on the SIX Swiss Exchange, on March 22, 2024. At the recent A